Meridian Life Science Whitepapers
Benefits of multiplex testing for the differential diagnosis of COVID-19, Flu, and RSV in a busy flu season
This year’s winter season is anticipated to be a difficult one as experts warn of a “twindemic” with surges of both influenza and COVID-19 expected. The drop in seasonal temperature combined with people staying indoors traditionally creates a sharp increase in transmission of winter respiratory viruses such as flu and RSV. However, last year due to social distancing and mask-wearing policies, the flu season experienced a reprieve with historically low rates of influenza recorded. In contrast, this year as communities re-open and many of those policies are relaxed, experts predict large increases in transmission for COVID-19 and flu simultaneously. For a medical system that has already been under tremendous strain for the past 18 months, this news is concerning. Using tools such as multiplexing assays for flu, COVID, and RSV to diagnose and treat patients faster and more effectively becomes a necessary next step.
Meridian is the complete solution
Meridian offers diagnostic manufacturers the complete solution with over 3,000 antigens and antibodies covering more than 500 diseases and an extensive range of specialty qPCR/RT-qPCR master mixes and molecular enzymes all manufactured under ISO13485 regulations.
Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!